Daniel Bensen
Fortune : 5 M $ au 31/05/2026
Fortune : 5 M $ au 31/05/2026
Daniel Bensen is the founder of Tyra Biosciences, Inc., founded in 2018, and holds the title of Chief Discovery Officer since 2025.
Former jobs include Principal Scientist at Trius Therapeutics, Inc. from 2007 to 2014, and Head-Immunology & Protein Chemistry at Cidara Therapeutics, Inc. from 2014 to 2018.
Education includes an undergraduate degree from Point Loma Nazarene University and an MBA from USC Marshall School of Business.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TYRA BIOSCIENCE, INC 0,25% | 12/02/2026 | 146 981 ( 0,25% ) | 5 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| TYRA BIOSCIENCES, INC. | Fondateur | 02/08/2018 |
| Sociétés | Poste | Fin |
|---|---|---|
| CIDARA THERAPEUTICS | Corporate Officer/Principal | 01/11/2018 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Corporate Officer/Principal | 01/02/2014 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Point Loma Nazarene University
Point Loma Nazarene University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial drugs for the treatment of infections | Health Technology |
USC Marshall School of Business
USC Marshall School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in the discovery, development, and commercialization of novel anti-infectives | Health Technology |
Tyra Biosciences, Inc.
Tyra Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cancer treatment drug therapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national